Creative Touch Permanent Makeup and Aesthetics

The skin microbiome is not a passenger on the barrier but a working part of it. Staphylococcus epidermidis, the dominant commensal, secretes a sphingomyelinase that converts host sphingomyelin into ceramides, directly contributing to the structural lipid matrix the skin cannot fully replenish on its own. The commensal community also maintains the acid mantle pH at which ceramide-processing enzymes, antimicrobial peptides, and barrier repair mechanisms all operate optimally. Disruption – through harsh cleansers, broad-spectrum antimicrobials, or inflammatory barrier failure – does not simply reduce microbial diversity. It dismantles an active biochemical partnership that the barrier depends on.

The skin microbiome comprises the bacteria, fungi, viruses, mites, and archaea that colonise the skin surface, hair follicles, and sebaceous gland ducts. Across the average adult, this community encompasses hundreds of species, varying in composition by body site, age, sex, and environmental exposure. The forearm microbiome differs markedly from the perinasal microbiome; the follicular microbiome differs from the surface microbiome. What unites these ecologically distinct niches is a fundamental principle: the skin microbiome is not simply cohabiting with the barrier. It is actively contributing to barrier function, and the barrier is actively shaping the environment in which the microbiome can survive.

The Resident Community

The skin microbiome is broadly organised into four bacterial phyla – Actinobacteria, Firmicutes, Proteobacteria, and Bacteroidetes – with distribution shaped primarily by the sebum content and hydration of each site. Sebaceous areas (face, chest, back) are dominated by Cutibacterium acnes (formerly Propionibacterium acnes) and Malassezia fungi. Moist areas (axillae, groin) host higher densities of Corynebacterium and Staphylococcus species. Dry areas carry the highest microbial diversity, with Staphylococcus epidermidis predominating across most of the body surface. ^[19]

S. epidermidis is the most clinically significant commensal in the context of barrier function. Its dominance is not incidental, it reflects an active competitive advantage that includes producing antimicrobial compounds that suppress the growth of Staphylococcus aureus and other pathogens. Where S. epidermidis colonisation is healthy and dense, pathogenic colonisation is directly inhibited through bacteriocin secretion and niche competition. The relationship between commensal abundance and pathogen exclusion is not passive; it is the result of active chemical competition.

The Skin Virome: A Regulatory Layer Above the Bacteria

The skin microbiome is not composed solely of bacteria and fungi. A population of viruses – the skin virome – also inhabits the skin surface, and whilst the research here is at an earlier stage than the bacterial literature, its ecological significance is increasingly apparent.

The virome comprises two broad categories. The first is bacteriophages: viruses that infect and lyse bacterial cells rather than human cells. The dominant bacteriophage families on skin belong to the order Caudovirales, and their host targets mirror the bacterial community – Staphylococcus, Pseudomonas, and Klebsiella species are predicted infection targets of Caudoviricetes-class phages. ^[8] C. acnes-targeting phages are notably more abundant on healthy, non- acne skin than on acne-affected skin, suggesting a regulatory role in preventing the expansion of pathogenic C. acnes phylotypes – a phage-mediated contribution to the same community balance that the commensal bacterial competition mechanisms described above are maintaining. The second category is eukaryotic viruses, principally Papillomaviridae and Polyomaviridae, which persist as latent residents on healthy skin without causing disease in immunocompetent individuals. Cutaneous HPV infections persist on healthy skin for several years in the majority of carriers; Merkel cell polyomavirus (MCPyV) and HPyV6 are established constituents of the healthy skin virome rather than incidental transient visitors. ^{[7] [2]}

Virome composition mirrors the site-specific ecology of the bacterial community. A 2025 comprehensive reference catalog drawing on 2,760 skin metagenomes from six published studies found that oily skin sites are enriched in Papillomaviridae, dry sites in Autographiviridae and Inoviridae, and moist sites in Herelleviridae – a distribution pattern that aligns with the sebum, hydration, and pH gradients that shape bacterial community composition. ^[8] This site-specificity suggests the virome is not randomly distributed but ecologically shaped by the same microenvironmental variables that govern the bacterial layer beneath it.

The virome’s relationship to S. aureus is clinically significant at two levels. Bacteriophages integrated into the S. aureus chromosome as prophages carry accessory virulence genes – an established feature of S. aureus pathogenicity – and can mediate horizontal transfer of methicillin-resistance encoding plasmids between strains, making the virome an active participant in S. aureus virulence gene dissemination rather than merely a passive ecological regulator. Conversely, exogenous bacteriophages targeting S. aureus demonstrate high specificity, the ability to disrupt biofilms, and minimal impact on commensal organisms – the biological rationale for phage therapy as an emerging complement to antibiotic and CAP-based dysbiosis management.

The skin virome is real, ecologically structured, and functionally active in ways that the bacterial-only model does not capture – but its contribution to barrier health, dysbiosis dynamics, and clinical outcomes is not yet characterised with the precision that the bacterial literature has achieved. The phage–C. acnes and phage–S. aureus relationships are the most clinically legible threads at present. The eukaryotic virome’s role in healthy skin homeostasis, and the conditions under which latent viral residents contribute to skin pathology, remains an active but unresolved research area.

S. epidermidis and Ceramide Production: A Symbiotic Mechanism

The most precisely characterised contribution of the skin microbiome to barrier function is one discovered only recently. S. epidermidis secretes a sphingomyelinase encoded by the sph gene that cleaves host sphingomyelin on the skin surface, generating ceramides as a byproduct of the bacterium’s own nutrient acquisition. The ceramides produced by this enzymatic activity are incorporated into the stratum corneum lipid matrix. ^[19]

In mouse models using sph-knockout S. epidermidis that lacks sphingomyelinase activity, skin ceramide levels fell significantly and transepidermal water loss (TEWL) increased in damaged skin, entirely reversing when normal S. epidermidis was reintroduced. The bacterium benefits from the phosphocholine released by sphingomyelin cleavage; the skin benefits from the ceramide production. ^[19] This is not metabolic coincidence, it is a well-characterised symbiotic mechanism in which the bacterium’s nutrient acquisition pathway is simultaneously performing barrier maintenance.

The clinical implication is precise: a skin surface depleted of S. epidermidis, whether through over-cleansing, broad-spectrum antimicrobial product use, or the dysbiosis that follows inflammatory barrier disruption, loses not just a resident organism but a ceramide synthesis contribution that the keratinocyte machinery alone does not fully compensate for. Ceramide depletion and microbiome disruption are not independent events. They are mechanistically linked through the sphingomyelinase pathway.

The Acid Mantle as Microbial Architecture

The pH of the stratum corneum surface, maintained between approximately 4.5 and 5.5 in healthy skin, is not merely a byproduct of free fatty acid secretion. It is the structural environment in which the entire microbiome operates, and the relationship is bidirectional: the microbiome helps maintain the acid mantle, and the acid mantle determines which organisms can survive on the skin surface.

S. aureus has a pH growth optimum of approximately 7.0–7.5. At pH 4.5–5.5, its adhesion to keratinocytes is significantly reduced; the genes encoding its keratinocyte-binding proteins, including clumping factor B, are expressed at lower levels in acidic conditions. ^[4] Each unit reduction in pH from neutral reduces S. aureus colonisation capacity substantially; each unit elevation in pH from the healthy acid mantle baseline measurably increases it. The acid mantle is, among other things, a microbial selection filter. It favours acid-tolerant commensals over alkaline-preferring pathogens.

Antimicrobial peptides (AMPs), including human beta-defensins and cathelicidins produced by keratinocytes, also have pH optima in the acidic range. At neutral or alkaline pH, AMP activity diminishes significantly, meaning the skin’s innate immune defence is structurally dependent on the same acid environment that maintains commensal dominance. An alkaline surface does not simply allow pathogen growth; it simultaneously disarms the peptides that would ordinarily suppress it.

The S. aureus Dysbiosis Loop

When barrier dysfunction is established – whether through genetic filaggrin deficiency, acquired IL-4/ IL-13-driven FLG suppression, or ceramide depletion – the resulting rise in stratum corneum pH creates conditions in which S. aureus colonisation becomes not only possible but self-sustaining.

S. aureus colonises compromised barrier skin, but its presence then amplifies the barrier disruption through multiple active mechanisms: its proteases degrade tight junction proteins; it directly suppresses filaggrin expression in keratinocytes; it activates the Th2 inflammatory pathway that elevates IL-4 and IL-13, which further suppress FLG transcription. ^[6] Filaggrin deficiency simultaneously reduces the urocanic acid (UCA) and pyrrolidone carboxylic acid (PCA) production that normally acidifies the skin surface and inhibits S. aureus adherence, removing the chemical environment that would otherwise limit S. aureus growth.

This is the same filaggrin–barrier feedback loop established in the Filaggrin entity, but with the microbial dimension now made explicit: the loop has a microbial amplifier embedded within it. Barrier → pH rise → S. aureus colonisation → filaggrin suppression → worse barrier → worse pH → more S. aureus. The loop cannot be fully broken by addressing barrier lipids alone if the microbial driver is active. Resolving S. aureus colonisation is part of the same recovery cycle.

Microbiome Diversity as a Resilience Signal

Healthy skin microbiome diversity inversely correlates with atopic dermatitis severity: the more diverse the bacterial community, the better the barrier tends to function, and the more dominant S. epidermidis relative to S. aureus. ^[5] Diversity matters because a richer microbial community provides more complete occupation of ecological niches, more varied AMP stimulation of the innate immune system, and more redundancy in the ceramide-supporting and acid mantle-maintaining functions that individual species provide.

What reduces diversity is important: broad-spectrum topical antibiotics; highly alkaline cleansers; excessive hand sanitiser use; prolonged systemic antibiotic courses; and paradoxically, barrier disruption itself, which reduces the environmental stability that diverse communities require. The skin microbiome is most resilient on well-functioning, appropriately acidic, lipid-intact barrier skin. Barrier health and microbiome health are self-reinforcing in both directions, a fact that the S. epidermidis ceramide mechanism makes structurally precise rather than merely conceptual.

Biofilm and the Skin Surface

The planktonic state – free-floating, individual bacteria – is the form most familiar from classical microbiology. Biofilm is something categorically different: a structured, polymicrobial community in which bacteria attach to a surface or to one another, encase themselves in a self-produced extracellular polysaccharide (EPS) matrix, and coordinate behaviour through quorum-sensing chemical signals. On skin, the organisms most clinically relevant to biofilm formation include Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, and Cutibacterium acnes within follicular units. The shift from planktonic to biofilm state is not merely a change in spatial organisation – it represents a fundamental change in physiology, gene expression, and susceptibility profile.

Why biofilm bacteria behave differently from planktonic bacteria

The EPS matrix serves multiple simultaneous functions. Structurally, it provides architectural scaffolding and retains nutrients and signalling molecules within the community. Defensively, it functions as a physical diffusion barrier: charged antimicrobials – including chlorhexidine and povidone-iodine – penetrate poorly through mature EPS, requiring extended contact time to reach the underlying bacteria at bactericidal concentrations. Within a mature biofilm, nutrient and oxygen gradients develop between the surface and the core. Bacteria in the core, deprived of nutrients and oxygen, enter a state of metabolic dormancy. These are persister cells: organisms that are not killed by antibiotics targeting active metabolic processes – cell wall synthesis, protein synthesis, DNA replication – because those processes have slowed or halted. On restoration of favourable conditions, persister cells resume replication and repopulate the biofilm, explaining why biofilm-associated infections recur after antibiotic courses that transiently reduce surface bacterial load ^[17].

A further consequence of the biofilm state is accelerated horizontal gene transfer (HGT). The close proximity of organisms within the biofilm community, combined with the EPS matrix providing a stable environment for conjugation and transformation, means that resistance genes move between organisms more readily than in planktonic populations. HGT has been shown to occur more frequently in biofilms than in planktonic cultures, providing a mechanism by which resistance acquisition can spread rapidly across species boundaries within the same biofilm community ^[9].

Immune evasion

The clinical significance of biofilm is captured precisely by the evidence: biofilm bacteria are less susceptible to the body’s immune defence system, and consequently biofilm-associated infection can persist for a prolonged period and progress from an acute to a chronic infection.

The immune evasion mechanism operates at several levels. The EPS matrix physically shields bacteria from neutrophil phagocytosis – the first cellular line of defence against bacterial invasion. Complement activation occurs at the biofilm surface but its effectors are neutralised or diluted before reaching the core. Studies in S. aureus biofilm models have demonstrated that even small bacterial aggregates (approximately 50 µm²) actively resist neutrophil-mediated killing – and critically, these aggregates cause neutrophil lysis rather than being cleared. Biofilm therefore does not simply evade the immune response; it weaponises the failure of that response, inducing localised tissue damage through lysed neutrophils whilst bacteria persist beneath. Delayed neutrophil recruitment to sites of bacterial colonisation creates a critical window in which nascent biofilm establishes and acquires tolerance to subsequent immune attack ^[12].

Adaptive immunity is similarly impaired: antibody penetration into mature biofilm is limited by matrix thickness, and the chronic inflammatory response that persistent biofilm sustains – prolonged, but ineffective at clearance – contributes to progressive tissue damage rather than resolution ^[15]. Paradoxically, neutrophil extracellular traps (NETs), generated in response to biofilm, can themselves contribute to biofilm structural stability through the extracellular DNA scaffold they provide, compounding rather than resolving the problem ^[1].

Biofilm on intact skin

Under intact barrier conditions, commensal biofilm is not pathological. S. epidermidis forms biofilm communities in follicular niches as part of its normal ecology on sebaceous and moist skin sites. This commensal biofilm exists in stable, low-virulence form, regulated by quorum-sensing signals and held in check by the acid mantle, the microbiome’s competitive ecology, and the constitutive antimicrobial peptide environment at the surface. The clinical risk emerges specifically when the physical barrier is breached.

The injectable needle breach context

When a needle punctures skin, it traverses the stratum corneum and enters the dermis – a normally sterile tissue compartment. The passage is not sterile: the needle tracks through the surface biome on its path inward. If the surface at the entry point carries biofilm-competent organisms – S. aureus, P. aeruginosa, or high-density S. epidermidis – fragments of disrupted biofilm or planktonic cells released from disrupted communities are transported into sub-barrier tissue.

This is the mechanistic link between surface biofilm and injection-site infection severity. It is not the mere introduction of bacteria that distinguishes biofilm-associated outcomes from planktonic contamination: in dermis and subcutis, the injected material (filler, PRP, botulinum toxin solution, polynucleotide) can serve as a substrate for re-establishment, and the EPS exclusion mechanism – which made the organism difficult to clear on the surface – now operates in a tissue environment where immune clearance is structurally impaired by the matrix. Bacterial colonisation of filler sites has been shown to lead to biofilms that are extremely difficult to treat, with early complications including abscess and cellulitis and late complications extending to chronic granulomatous reactions ^[18]. The association between biofilm-mediated complications and technique and product quality is well recognised in the injectable complication literature and has been documented in retrospective complication case series ^[10].

The practical implication for pre-treatment assessment: the question is not only “are there bacteria on this skin?” but “is there biofilm on this skin, and is the antiseptic protocol designed to penetrate and disrupt it?”

Sweat-Derived Antimicrobials: Lysozyme, Dermcidin, and the Constitutive Surface Defence

Lysozyme (muramidase, EC 3.2.1.17) is an enzyme present across human secretions including tears, saliva, nasal mucus, breast milk, and sweat. Its antimicrobial mechanism is enzymatic and specific: it cleaves the β-1,4-glycosidic bond between N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) in bacterial peptidoglycan. This linkage is load-bearing to the bacterial cell wall – its hydrolysis disrupts structural integrity and causes osmotic lysis in organisms whose peptidoglycan is accessible. Gram-positive bacteria, which lack an outer membrane and present peptidoglycan at the cell surface, are selectively vulnerable. Gram-negative bacteria possess an outer membrane that shields the peptidoglycan layer; lysozyme’s efficacy against Gram-negatives therefore depends on concurrent disruption of this outer membrane, which is where cationic antimicrobial peptides (AMPs) such as defensins and cathelicidins act synergistically with lysozyme in the mixed secretory environment.

The skin surface antimicrobial system operates constitutively – continuously, independent of adaptive immune priming. Eccrine sweat glands are the primary secretory mechanism through which this system is delivered to the skin surface, and the antimicrobial composition of eccrine secretion is diverse. The dominant AMP in human eccrine sweat is dermcidin: a protein constitutively expressed in eccrine sweat glands, secreted into sweat, transported to the epidermal surface, and processed post-secretion by cathepsins into at least 14 antimicrobial peptide variants with broad-spectrum activity maintained across the pH and salt concentration range of human sweat ^[16]. It is notable that LL-37 and alpha/beta-defensins are not detected in significant quantities in eccrine sweat – they arrive at the skin surface by other routes – making dermcidin the distinctive eccrine-sweat AMP ^[13]. Lactoferrin, an iron-chelating antimicrobial glycoprotein, has also been directly confirmed in human sweat by proteomic analysis, contributing a bacteriostatic mechanism through iron sequestration ^[11].

Lysozyme contributes to this constitutive surface antimicrobial environment as a component of the secretory output delivered to the skin surface through sweating. The function of eccrine secretion is therefore not solely thermoregulatory: each episode of sweating delivers a bolus of antimicrobial molecules – dermcidin-derived peptides, lactoferrin, lysozyme, and secretory IgA – that renews the chemical defence layer that the acid mantle and lipid environment alone cannot fully provide.

The clinical corollary is demonstrated by atopic dermatitis, in which deficiency in dermcidin-derived antimicrobial peptides in sweat correlates with impaired in vivo skin defence and higher rates of S. aureus colonisation in the affected population ^[14]. The loss of sweat-derived antimicrobial capacity is not a theoretical concern – it has measurable consequences on the microbiological phenotype of the skin surface. Clients with hypohidrosis, whether constitutional, medication-related, or resulting from prior botulinum toxin treatment to sweat glands, may have a transiently reduced surface antimicrobial screen. This is contextually relevant when advising on microbiome-supportive homecare.